Read by QxMD icon Read

"Immunoglobulin A nephropathy"

Alaa A Ali, Dana A Sharif, Safa E Almukhtar, Kais Hasan Abd, Zana Sidiq M Saleem, Michael D Hughson
BACKGROUND: Estimates of the incidence of glomerulonephritis (GN) and end-stage renal disease (ESRD) in an Iraqi population are compared with the United States (US) and Jordan. METHODS: The study set consist of renal biopsies performed in 2012 and 2013 in the Kurdish provinces of Northern Iraq. The age specific and age standardized incidence of GN was calculated from the 2011 population. ESRD incidence was estimated from Sulaimaniyah dialysis center records of patient's inititating hemodialysis in 2017...
October 11, 2018: BMC Nephrology
Hea Min Jang, Hee Sun Baek, Jung-Eun Kim, Ju Young Kim, Yeon Hee Lee, Hee Yeon Cho, Yon Ho Choe, Ben Kang, Byung-Ho Choe, Bong Seok Choi, Min Hyun Cho
Purpose: The incidence of inflammatory bowel disease (IBD) is rapidly increasing, and several reports have described the renal complications of IBD. We sought to evaluate the clinical manifestations of renal complications in children with IBD in order to enable early detection and prompt treatment of the complications. Methods: We retrospectively reviewed the medical records of 456 children and adolescents aged <20 years who had been diagnosed with IBD since 2000...
September 12, 2018: Korean Journal of Pediatrics
F B Vincent, R Kandane-Rathnayake, A Y Hoi, L Slavin, J D Godsell, A R Kitching, J Harris, C L Nelson, A J Jenkins, A Chrysostomou, M L Hibbs, P G Kerr, M Rischmueller, F Mackay, E F Morand
Introduction We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE). Methods We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified...
October 9, 2018: Lupus
Ming Li, Xueqing Yu
Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis throughout the world and a major cause of end-stage renal disease among East Asian population. It is widely considered that genetic factors play an important role in the pathogenesis of IgAN. The genetic studies of IgAN, is from the association studies of candidate genes and family-based designs, to the genome-wide association studies. Altogether there are five large genome-wide association studies performed, which have identified multiple susceptibility loci for IgAN, including several novel loci found in Chinese population...
October 2018: Nephrology
Yue-Miao Zhang, Hong Zhang
Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and the most common cause of end-stage renal disease in young adults. However, there are still no specific therapies capable of targeting key pathways involved in disease pathogenesis. Recently, many large randomized controlled trials have been reported, such as Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy, Targeted-release Budesonide Versus Placebo in Patients with IgA Nephropathy and Therapeutic Evaluation of Steroids in IgA Nephropathy Global, which are considered to update the 2012 Kidney Disease: Improving Global Outcomes Guideline...
October 2018: Nephrology
Ying Tan, Ming-Hui Zhao
Complement activation has been identified to play a vital role in the pathogenesis of many glomerulonephritis, either as direct complement activation-driven factor in thrombotic microangiopathy and C3 glomerulopathy, and/or as an important contributor in lupus nephritis and anti-neutrophil cytoplasmic antibody-associated vasculitis. Recent studies indicated that complement activation may also play roles in the pathogenesis of immunoglobulin A nephropathy and focal segmental glomerulosclerosis. Interestingly, monoclonal immunoglobulins/light chains from patients with monoclonal gammopathy may interfere with complement activation and thus indirectly result in complement-mediated glomerulonephritis...
October 2018: Nephrology
Cihan Heybeli, Mehmet Ası Oktan, Serkan Yıldız, Hayri Üstün Arda, Mehtat Ünlü, Caner Çavdar, Aykut Sifil, Ali Çelik, Sülen Sarıoğlu, Taner Çamsarı
BACKGROUND: Glomerular immunoglobulin G deposition in patients with immunoglobulin A nephropathy (IgAN) has been shown to be associated with adverse renal outcomes. Clinical significance of mesangial immunoglobulin M (IgM) deposition in these patients remains to be proven. METHODS: One hundred patients who had a diagnosis of IgAN between 2001 and 2017 were enrolled. Patients were divided into two groups based on mesangial IgM deposition status. Groups were compared for demographic, clinical, and pathologic variables at baseline and in follow-up...
October 6, 2018: Clinical and Experimental Nephrology
Hee Sun Baek, Man Hoon Han, Yong Jin Kim, Min Hyun Cho
INTRODUCTION: Few studies have reported the association between the complement cascade and pediatric immunoglobulin A nephropathy (IgAN). This study aimed to investigate the association between C4d staining positivity and the clinical/histopathological characteristics of pediatric patients with IgAN. METHODS: Children diagnosed with IgAN through renal biopsy were retrospectively reviewed. Renal biopsy specimens were stained using C4d immunohistochemistry. RESULTS: Among the 56 patients, 31 (55...
October 1, 2018: Fetal and Pediatric Pathology
Yue Ji, Kang Yang, Bo Xiao, Jin Lin, Qingyun Zhao, Maheshkumar Satishkumar Bhuva, Hongtao Yang
BACKGROUND: Published reports evaluating whether angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (ACEI/ARB) therapy could bring improvements to the prognosis of immunoglobulin A nephropathy (IgAN) have yielded confusing results, which entails a systematic review of those reports. In this study, we summarized currently available evidence from randomized controlled trials (RCTs) that evaluated the effect of ACEI/ARB therapy of IgAN. METHODS: PubMed, International comprehensive biomedical information bibliographic database produced by the National Library of Medicine (MEDLINE), Excerpt Medica Database (EMBASE), and Cochrane Library and article reference lists were searched for RCTs that compared ACEI/ARB with placebo and any other nonimmunosuppressive agents except RAAS agents for treating IgAN...
September 30, 2018: Journal of Cellular Biochemistry
Yoshinosuke Shimamura, Takuto Maeda, Yufu Gocho, Yayoi Ogawa, Kunihiko Tsuji, Hideki Takizawa
Immunoglobulin A nephropathy is the most common primary glomerulonephritis worldwide, and it can be associated with liver disease. However, cases of Immunoglobulin A nephropathy secondary to Wilson's disease are very rare. A 20-year-old Japanese man presented with microscopic hematuria, proteinuria, and renal dysfunction. A renal biopsy showed mesangial cell proliferation, immunoglobulin A deposition, and electron-dense deposit in the mesangial areas, all of which are consistent with Immunoglobulin A nephropathy...
September 25, 2018: CEN Case Reports
J Floege, P Boor, M J Moeller
Glomerulonephritides essentially all belong to the rare diseases; however, they are the most common cause of end-stage renal disease in young adults. Besides obtaining a specific diagnosis via a renal biopsy, assessing the prognosis constitutes the other essential step in the work-up, since this enables a decision to be made on whether supportive care with relatively few adverse effects is sufficient or whether additional immunosuppressive therapy is required. The latter is discussed focusing on the most common European types of glomerulonephritis: immunoglobulin A nephropathy, membranous glomerulonephritis, minimal change nephropathy and focal segmental glomerulosclerosis...
September 24, 2018: Der Internist
A Carosso, M Zonca, L Colla, F Borella, L Daniele, C Benedetto
Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis and is increasingly encountered in pregnancy. The obstetric and renal outcomes of pregnancy are controversial, however. Women with IgAN are at higher risk of hypertension, preeclampsia and foetal loss; the prognosis is worse for those who have advanced chronic kidney disease and proteinuria. Here we report the case of a 32-year-old nulliparous woman with chronic hypertension who conceived during an active phase of her IgAN, which had been diagnosed 8 years earlier...
October 2018: Case Reports in Women's Health
Wei-Yi Guo, Qing-Zhen Liu, Li Zhu, Zeng-Yan Li, Si-Jun Meng, Su-Fang Shi, Li-Jun Liu, Ji-Cheng Lv, Ping Hou, Hong Zhang
BACKGROUND: In immunoglobulin A nephropathy (IgAN), complement activation occurs in both the systemic circulation and in situ (glomerular). A recent IgAN-genome-wide association study (GWAS) identified 1q32 as an IgAN susceptible locus that contained the complement regulatory protein coding gene complement factor H (CFH). Here, we explored the combined genetic effects of coding and noncoding variants in CFH, rs6677604 and rs800292 on complement activation in IgAN. METHODS: In total, 1,194 IgAN patients and 900 healthy controls who were the same as the Beijing Discovery Cohort in our recent IgAN-GWAS were recruited...
August 2018: American Journal of the Medical Sciences
Ryoya Tsunoda, Joichi Usui, Junichi Hoshino, Takayuki Fujii, Satoshi Suzuki, Kenmei Takaichi, Yoshifumi Ubara, Kunihiro Yamagata
BACKGROUND: Corticosteroids are widely used to reduce the urine protein levels of patients with immunoglobulin A nephropathy (IgAN). However, their potential preventive effects on end-stage kidney disease (ESKD) are unclear. METHODS: We previously performed a large-scale, long-term multicenter cohort study of patients with biopsy-proven IgAN treated between 1981 and 2013 (n = 1923). Based on the results, we reported that corticosteroids pulse therapy was potentially effective for the treatment of patients with an eGFR ≥30 ml/min/1...
September 6, 2018: BMC Nephrology
Shikai Liang, Juan Jin, Xiaogang Shen, Xinxin Jiang, Yiwen Li, Qiang He
Triptolide is often used to treat patients with immunoglobulin A nephropathy (IgAN), especially in Asia. However, its detailed mechanism remains unclear. In vitro experiments were conducted with podocytes exposed to aggregated IgA (aIgA)-MSC1097-conditioned media. A total of four groups were compared in this study: A control group (CON); a healthy supernatant group (HEAs); an IgAN supernatant group (IgANs); and a triptolide group (TRI). First, aggregated IgA1 (aIgA1) was generated by heating monomeric IgA1 (mIgA1) from IgAN patients or healthy subjects...
September 2018: Experimental and Therapeutic Medicine
Jian-Nan Zheng, Tong-Dan Bi, Lin-Bo Zhu, Lin-Lin Liu
The efficacy and safety of mycophenolate mofetil (MMF) for immunoglobulin A nephropathy (IgAN) remains debatable. Therefore, the present meta-analysis was conducted with randomized controlled trials (RCTs). PubMed/MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were analyzed to identify eligible trials. The pooled risk ratio (RR) with 95% confidence interval (CI) was estimated for all the dichotomous outcome measures. A total of eight RCTs with nine publications (n=510 patients) were included...
September 2018: Experimental and Therapeutic Medicine
Ye Feng, Lin-Li Lv, Wei-Jun Wu, Zuo-Lin Li, Jun Chen, Hai-Feng Ni, Le-Ting Zhou, Tao-Tao Tang, Feng-Mei Wang, Bin Wang, Ping-Sheng Chen, Steven D Crowley, Bi-Cheng Liu
IgA nephropathy (IgAN) features variable renal pathology and a heterogeneous clinical course. Our aim was to search noninvasive biomarkers from urinary exosomes for IgAN patients; membrane nephropathy and minimal change disease were included as other glomerulopathy controls. Transmission electron microscopy and nanoparticle tracking analysis confirmed the size and morphology characteristic of urinary exosomes. Exosome markers (Alix and CD63) as well as renal cell markers (AQP2 and nephrin) were detected, which indicate the renal origin of urinary exosomes...
August 22, 2018: American Journal of Pathology
Yuyan Tang, Haidong He, Weiqian Sun, Pin Hu, Xia Chen, Xudong Xu
Currently, there is no clear evidence that advocates the widespread use of corticosteroids for the treatment of immunoglobulin A nephropathy (IgAN) with minimal proteinuria (<1 g/day). The recent Kidney Disease: Improving Global Outcomes Clinical Practice Guideline recommends supportive corticosteroid treatment. In the present study, 45 IgAN patients with high renal pathological scores and minimal proteinuria were enrolled. The patients were randomly divided into two groups. The treatment group received methylprednisolone tablets in addition to angiotensin‑converting‑enzyme inhibitor (ACE‑I) and/or angiotensin‑receptor blocker (ARB) treatment...
August 21, 2018: Molecular Medicine Reports
Bin Zhu, Dong-Rong Yu, Ji-Cheng Lv, Yi Lin, Qiang Li, Jia-Zhen Yin, Yuan-Yuan Du, Xuan-Li Tang, Li-Chan Mao, Qiu-Fen Li, Yue Sun, Ling Liu, Xian-Fa Li, Dan Fei, Xin-Yi Wei, Cai-Feng Zhu, Xiao-Xia Cheng, Hong-Yu Chen, Yong-Jun Wang
BACKGROUND: The role of serum uric acid (SUA) level in the progression of Immunoglobulin A nephropathy (IgAN) remains controversial. METHODS: In a cohort of 1,965 cases with biopsy-proven IgAN, we examined the associations of SUA concentration with the primary outcome of a composite of all-cause mortality or kidney failure (defined as a reduction of estimated glomerular filtration rate [eGFR] by 40% from baseline, requirements for dialysis and transplantation), or the outcome of kidney failure alone, assessed using Cox and logistic regression models, respectively, with adjustment for confounders...
2018: American Journal of Nephrology
Li Tan, Yi Tang, Wei Peng, Bechu Shelley Mathew, Wei Qin
BACKGROUND/AIMS: Treatment of advanced Immunoglobulin A nephropathy (IgAN) patients with estimated glomerular filtration rate (eGFR) below 45 mL/min per 1.73 m2 remains inconsistent. The aim of this study is to compare the effects of corticosteroid and immunosuppressant therapies among these patients. METHODS: A total of 201 adult patients with advanced IgAN (eGFR < 45 mL/min/1.73 m2 and proteinuria > 1 g/24h at biopsy) grouped into supportive care (SC), steroids alone (CS), and steroids plus immunosuppressant (IT) groups, were investigated between 30th December 2002 and 30th June 2016...
2018: Kidney & Blood Pressure Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"